Literature DB >> 7231514

Scintigraphic localization of pheochromocytoma.

J C Sisson, M S Frager, T W Valk, M D Gross, D P Swanson, D M Wieland, M C Tobes, W H Beierwaltes, N W Thompson.   

Abstract

We used a new radiopharmaceutical agent, [131I]meta-iodobenzylguanidine ([131I]MIBG), to produce scintigraphic images of pheochromocytomas in eight patients. One day or more after injection, the only normal organ that displayed distinct concentrations of radioactivity was the urinary bladder. The [131I]MIBG was probably concentrated in adrenergic vesicles; in tissues where vesicles are numerous, such as pheochromocytomas, the radionuclide was retained for days. The spectrum of pheochromocytomas shown the scintigrams was broad: intra-adrenal and extraadrenal in location, benign and malignant in character, 0.2 to 65 g in weight, and with different hormone patterns in secretion. Tumors in four patients were not detected by computed tomography. In one patient, reoperation was undertaken only because the scintigram located the extra-adrenal tumors and thereby directed the surgeon's exploration. The method offers hope of safe and reliable localization of pheochromocytomas in their many guises.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7231514     DOI: 10.1056/NEJM198107023050103

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  82 in total

1.  False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.

Authors:  Jay S Fonte; Jeremyjones F Robles; Clara C Chen; James Reynolds; Millie Whatley; Alexander Ling; Leilani B Mercado-Asis; Karen T Adams; Victoria Martucci; Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2012-02-13       Impact factor: 5.678

2.  Multiple endocrine neoplasia type 2 with malignant pheochromocytoma--long term follow-up of a case by 131I-meta-iodobenzylguanidine scintigraphy.

Authors:  H Namba; H Kondo; S Yamashita; H Kimura; N Yokoyama; M Tsuruta; A Sato; M Izumi; H Kinoshita; S Hakariya
Journal:  Ann Nucl Med       Date:  1992-05       Impact factor: 2.668

Review 3.  Mechanisms of storage and exocytosis in neuroendocrine tumors.

Authors:  Manfred Gratzl; Martin Breckner; Christian Prinz
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

4.  ACP Broadsheet No 127: April 1991. Measurement of catecholamines and their metabolites in urine.

Authors:  C Weinkove
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

5.  A practical, automated synthesis of meta-[(18)F]fluorobenzylguanidine for clinical use.

Authors:  Bao Hu; Amy L Vāvere; Kiel D Neumann; Barry L Shulkin; Stephen G DiMagno; Scott E Snyder
Journal:  ACS Chem Neurosci       Date:  2015-09-11       Impact factor: 4.418

Review 6.  Contemporary adrenal scintigraphy.

Authors:  Milton D Gross; Anca Avram; Lorraine M Fig; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-25       Impact factor: 9.236

7.  Functional paraganglioma.

Authors:  Gokulakrishnan Balasubramanian; Vallikantha Nellaiappan
Journal:  BMJ Case Rep       Date:  2014-02-20

8.  Radionuclide therapy of malignant pheochromocytoma with 131I-MIBG.

Authors:  Y Nakabeppu; M Nakajo
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

9.  The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience.

Authors:  L Troncone; V Rufini; P Montemaggi; F M Danza; A Lasorella; R Mastrangelo
Journal:  Eur J Nucl Med       Date:  1990

10.  Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy.

Authors:  M Shimizu; N Sugihara; Y Kita; K Shimizu; Y Horita; K Nakajima; J Taki; R Takeda
Journal:  Br Heart J       Date:  1992-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.